Clinical Trials Browser

Phase 2 × vitespin × Genitourinary × Clear all

NCT01147536 2021-06-03

Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence

Phase 2 Terminated

12 enrolled 5 charts

Carcinoma, Renal Cell